Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial)

2018109 citationsJournal Article

Authors

Yoshio Sumida · Aichi Medical University

Kenta Murotani · Kurume University

Miyoko Saito · Kishokai Medical Corporation

Atsuko Tamasawa · Kishokai Medical Corporation

Yusuke Osonoi · Kishokai Medical Corporation

Masashi Yoneda · Aichi Medical University

Takeshi Osonoi ·

Abstract

Luseogliflozin can be a novel promising agent for the treatment of T2DM patients with NAFLD. Prospective randomized controlled trials are warranted to confirm this impact of luseogliflozin onT2DM with NAFLD.

Topics & Keywords

Liver Disease Diagnosis and Treatment Diet, Metabolism, and Disease Drug Transport and Resistance Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology Research

Volume 49, Issue 1, pp. 64-71

DOI: 10.1111/hepr.13236

Field-Weighted Citation Impact: 9.33